A Very Early Rehabilitation Trial

AVERT is a Phase III, international, multicentre, single blind trial comparing earlier onset and higher dose rehabilitation (mobility emphasis) with standard care. This is an investigator driven trial with NHMRC grant support. Primary outcome is death/disability at 3 months. A cost effectiveness sub-study runs beside the trial. Inclusion criteria are broad: patients > 18 years (no upper age limit), admitted <24 hours of ischemic and haemorrhagic stroke to a stroke unit. Those treated with rtPA are also eligible. Intervention is provided by a nurse/physiotherapist team.


24 June 2021